Skip to main content

Table 2 Response of MM cell lines towards various treatments

From: Estrogenic or antiestrogenic therapies for multiple myeloma?

Cell lines

Compounds

Ref.

 

2ME2

Tam

4HT

Tor

Ral

ICI

RU

 

ANBL6

CCA + Ap.*

      

[5]

Karpas 620

  

No

    

[11]

       

No

**

KAS-6/1

CCA + Ap.

      

[5]

KMM-1

 

CCA + Ap.

 

CCA + Ap.

   

[10]

LP-1

  

CCA + Ap.

    

[11]

      

CCA

CCA

**

MM.1S/R

Ap.

      

[4]

NCI-H929

  

CCA + Ap.

    

[11]

      

Ap.

Ap.

**

OCI-My5

CCA + Ap.

      

[4]

  

CCA + Ap.

     

[5]

OPM-2

  

No

    

[11]

      

CCA

CCA

**

RPMI 8226

Ap.

      

[4]

 

CCA

      

[5]

   

CCA + Ap.

    

[11]

 

CCA + Ap.

 

CCA + Ap.

No

 

CCA + Ap.

 

[12]

  

CCA + Ap.

  

CCA + Ap.

  

[13]

      

Ap.

Ap.

**

U266

 

CCA + Ap.

 

CCA + Ap.

   

[10]

   

CCA + Ap.

    

[11]

  

CCA + Ap.

CCA + Ap.

  

CCA + Ap.

 

[12]

  

CCA + Ap.

  

CCA + Ap.

  

[14]

      

No

No

**

  1. Presented cell lines were chosen as in Table 1. Cell lines were treated in vitro with micromolar concentrations of 2ME2, SERMs or SERDs (0.5–50 μM) and drug effects were detected 24–72 h later. Cell cycle arrest was demonstrated essentially by flow cytometry sorting of propidium iodide-stained cells, apoptosis was assessed with different techniques such as annexin V staining, caspase activity assays, mitochondrial membrane potential measurement, and TUNEL method. * CCA, cell cycle arrest; Ap., apoptosis; Tam, tamoxifene; Tor, toremifene, Ral, raloxifene. ** Gauduchon et al, submitted.